New combo therapy may cut needle pokes for macular degeneration patients
NCT ID NCT00527475
First seen Jan 07, 2026 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tested whether adding a light-activated drug treatment (photodynamic therapy) to the standard injection therapy (ranibizumab) could reduce the number of injections needed for wet macular degeneration. 60 participants aged 50 and older with the condition were enrolled. The goal was to maintain vision while lowering the risks and burden of frequent eye injections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Associated Retinal Consultants
Ann Arbor, Michigan, 49301, United States
-
California Retina Consultants & Research Foundation
Santa Barbara, California, 93103, United States
-
Texas Retina Associates
Arlington, Texas, 76012, United States
Conditions
Explore the condition pages connected to this study.